Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BLDE SEC filings page on Stock Titan provides access to the regulatory history of Blade Air Mobility, Inc., which has since changed its name to Strata Critical Medical, Inc. and now trades on Nasdaq under the symbol SRTA, as disclosed in a Form 8-K dated August 29, 2025. These filings document the company’s evolution from a technology-powered air mobility platform combining passenger and medical operations into a focused medical logistics business.
Among the key documents are multiple Current Reports on Form 8-K. One Form 8-K filed on August 5, 2025 furnishes a press release announcing financial results for the quarter ended June 30, 2025 under Item 2.02 (Results of Operations and Financial Condition). Another Form 8-K filed on August 1, 2025 describes an Equity Purchase Agreement under Item 1.01, outlining the terms under which a subsidiary of Joby Aviation agreed to acquire Blade’s Passenger business, including the structure of cash or stock consideration, earn-out provisions, and related non-compete and commercial arrangements.
A subsequent Form 8-K filed on August 29, 2025 reports the completion of the Passenger business sale, details the consideration received in Joby Aviation common stock and potential additional amounts, and explains the company’s name change to Strata Critical Medical, Inc. and ticker change to SRTA. That filing also discusses related agreements, such as a restrictive covenant agreement and a commercial agreement giving Joby a role in providing certain medical transport services, and notes amendments to the company’s charter and bylaws.
Later 8-K filings under the Strata Critical Medical name, such as those dated September 16, 2025 and November 10, 2025, describe material events including the acquisition of Keystone Perfusion Services, LLC and the release of quarterly financial results. Together, these filings show how the company has shifted toward mission critical logistics and medical services for hospitals and healthcare providers.
On Stock Titan, users can review these BLDE-linked filings with AI-powered summaries that highlight the main terms of material agreements, changes in corporate structure, and key financial disclosures. Real-time updates from EDGAR, along with structured access to Forms 8-K and other reports, help investors quickly understand how Blade’s historical regulatory record connects to the current Strata Critical Medical (SRTA) listing.
Strata Critical Medical, Inc. entered into a new secured, asset-based revolving credit facility of up to $30.0 million with JPMorgan Chase Bank, N.A. and other lenders. The agreement allows the facility to be increased by up to an additional $20.0 million, providing extra borrowing capacity if conditions are met.
The ABL facility matures on January 30, 2029 and will bear interest, at Trinity Air Medical’s election, at an adjusted Term SOFR-based fixed rate plus a 2.00% margin or a one‑month Term SOFR floating rate plus a 2.00% margin. A 0.25% annual commitment fee applies to unused amounts.
The loans are guaranteed by Strata Critical Medical and its subsidiary Strata Critical, Inc. and are secured by first‑priority liens on substantially all personal property of the loan parties. The agreement contains customary covenants and events of default, including a springing minimum fixed charge coverage ratio of 1.05 to 1.00 when availability falls below specified thresholds. Proceeds are intended for working capital and general organizational purposes.
BlackRock, Inc. has reported a passive ownership stake in Strata Critical Medical Inc. Class A stock. BlackRock beneficially owns 4,384,945 shares, representing 5.1% of the outstanding Class A shares. It has sole power to vote 4,316,388 shares and sole power to dispose of 4,384,945 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and are not held for the purpose of changing or influencing control of the company.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine equity-related transaction. On 12/10/2025, 34,018 shares of Class A common stock were disposed of at $4.38 per share under transaction code F.
After this transaction, she beneficially owned 1,366,402 Class A shares, held directly. A footnote explains that the shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market.
Strata Critical Medical, Inc. reported an insider equity transaction by director and Co‑CEO and CFO William A. Heyburn on 12/10/2025. The filing shows 35,348 shares of Class A common stock were withheld by the company at $4.38 per share to cover tax obligations tied to vesting restricted stock units. After this tax withholding, he directly beneficially owned 1,368,088 shares of Class A common stock.
Strata Critical Medical, Inc. reported an insider transaction by an officer who serves as CEO of Trinity Air Medical. On 12/10/2025, the officer had 21,643 shares of Class A common stock withheld at $4.38 per share, recorded under transaction code F, in connection with tax withholding on vesting restricted stock units.
After this transaction, the officer beneficially owned 293,395 shares directly and 382,987 shares indirectly through a limited liability company of which the officer is the sole member. The filing describes the transaction as issuer share withholding to satisfy tax obligations related to equity compensation.
Strata Critical Medical, Inc. reported an insider tax-withholding transaction involving 3,716 shares of its Class A common stock. On 12/10/2025, Chief Accounting Officer Amir Cohen had 3,716 shares withheld at $4.38 per share to satisfy tax obligations triggered by the vesting of restricted stock units, and he now beneficially owns 117,626 shares directly.
Strata Critical Medical, Inc. (SRTA)11/20/2025, the director sold 11,000 shares of Class A common stock at a price of $4.37 per share, coded as an open-market sale (transaction code S). After this transaction, the director beneficially owns 113,897 shares directly. The filing is a single‑reporting‑person Form 4 and does not list any derivative securities activity.
Strata Critical Medical, Inc. filed a Form S-8 to register 12,104,544 shares of common stock for issuance under its 2021 Omnibus Incentive Plan. These shares support equity compensation for employees, directors and other service providers and are in addition to amounts previously registered under earlier Form S-8 filings. The newly registered pool includes shares added through the plan’s annual “evergreen” increase, shares recycled from expired or forfeited awards under a prior Fly Blade, Inc. plan, and shares from awards under the current plan that expired or were settled without stock issuance. The company incorporates by reference its recent 10-K, 10-Qs and 8-Ks and lists standard exhibits such as its charter, bylaws, the incentive plan and legal opinions.
Strata Critical Medical, Inc. reported an insider transaction by a director on a Form 4. On 11/19/2025, the reporting person sold 11,000 shares of Class A common stock at a weighted average price of $4.3122 per share, with individual trade prices ranging from $4.31 to $4.32. After this sale, the director beneficially owns 124,897 shares of the company’s Class A common stock, held directly. No derivative securities transactions were reported in this filing.
Strata Critical Medical (SRTA): Co-CEO, General Counsel, and Director Melissa M. Tomkiel exercised employee stock options and acquired 27,778 shares of Class A common stock at $0.18 per share on 11/07/2025 (transaction code M). Following the transaction, she beneficially owns 1,400,420 shares, held directly.
The exercised options relate to grants first exercisable on 05/07/2021 and expiring on 07/28/2030. After this activity, 276,960 stock options remain beneficially owned, held directly.
FAQ
What is the current stock price of Blade Air Mobility (BLDE)?
What is the market cap of Blade Air Mobility (BLDE)?
